Ascletis Begins U.S. Phase I Trials of Monthly Obesity Drugs
Hong Kong, China, August 10, 2026 Ascletis Pharma Inc. has announced the initiation of two Phase I clinical studies...
Ascletis Pharma
Advertisement
AusperBio Doses First Patient for AHB-171 HBV Clinical Study
San Francisco, August 3, 2026 AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. announced the initiation of patient dosing...
Ascletis Launches Global Phase III Trial of Oral GLP-1 ASC30
Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...
Ascletis Reports ASC37 Shows Superior Weight Loss in Obesity Study
Hong Kong, July 27, 2026 Ascletis Pharma Inc. announced that its investigational ASC37, a next-generation GLP-1R/GIPR/GCGR triple peptide agonist,...
Ribo Unveils Positive Phase 2a Data for Vortosiran in CAD
SHANGHAI, China and MÖLNDAL, Sweden, July 22, 2026 Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals...
Advertisements
Ascletis Reports Superior ASC36_35 Weight Loss Data at EASD 2026
HONG KONG, July 23, 2026 Ascletis Pharma Inc. has announced that new preclinical data for its investigational obesity therapy...
InnoCare Doses First Patient in ICP-B208 ADC Clinical Trial
BEIJING, China, July 6, 2026 InnoCare Pharma has announced a significant milestone in its oncology pipeline with the first...
Ascletis Submits FDA INDs for Next-Generation Obesity Drugs
HONG KONG, July 6, 2026 Ascletis Pharma Inc. has announced the submission of two Investigational New Drug (IND) applications...
Ascletis Showcases ASC30, ASC37 and ASC39 Obesity Data at ADA 2026
HONG KONG, June 8, 2026 Ascletis Pharma Inc. presented new clinical and preclinical data from its expanding obesity pipeline...
Ascletis Expands ASC30 Oral GLP-1 Program for Obesity Treatment
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
Advertisement
